Skip to main content
. 2012 Mar;1(1):54–60. doi: 10.3978/j.issn.2218-6751.11.01

Table 3. EGFR expression levels and overall survival in advanced NSCLC: analysis of data from the FLEX trial (30).

High EGFR expression
 Low EGFR expression
CT+Cetuximab CT CT+Cetuximab CT
Hazard ratio (95%) 0.73 (0.58-0.93) 0.99 (0.84-1.16)
Median survival, months 12.0 9.6 9.8 10.3
P Value 0.011 0.88
P Value for interaction 0.044